High plasma homocysteine concentrations are associated with plasma concentrations of thrombomodulin in patients with type 2 diabetes and link diabetic nephropathy to macroangiopathy

Metabolism: Clinical and Experimental

Volumn 52, Issue 11, 2003, Pages 1517-1522

  Okumura, Ki Ichi ^a   Aso, Yoshimasa ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; C PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HOMOCYSTEINE; INSULIN; ORAL ANTIDIABETIC AGENT; THROMBOMODULIN;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION FUNCTION; CREATININE CLEARANCE; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIET THERAPY; DISEASE ASSOCIATION; ENDOTHELIUM LESION; ENZYME IMMUNOASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONE BLOOD LEVEL; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; PROTEINURIA; STROKE; URINALYSIS;

EID: 0345374666     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(03)00324-X     Document Type: Article

References (31)

1. Stampfer MJ, Malinow MR, Willett WC, et al: A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 268:877-881, 1992
2. Perry IJ, Refsum H, Morris RW, et al: Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 346:1395-1398, 1995
3. van den Berg M, Stehouwer CD, Bierdrager E, et al: Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease. Arterioscler Thromb Vasc Biol 16:165-171, 1996
4. Hoogeveen EK, Kostense PJ, Beks PJ, et al: Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: A population-based study. Arterioscler Thromb Vasc Biol 18:133-138, 1998
5. Bostom AG, Shemin D, Verhoef P, et al: Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol 17:2554-2558, 1997
6. Wollesen F, Brattstrom L, Refsum H, et al: Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int 55:1028-1035, 1999
7. Emoto M, Kanda H, Shoji T, et al: Impact of insulin resistance and nephropathy on homocysteine in type 2 diabetes. Diabetes Care 24:533-538, 2001
8. Davies L, Wilmshurst EG, McElduff A, et al: The relationship among homocysteine, creatinine clearance, and albuminuria in patients with type 2 diabetes. Diabetes Care 24:1805-1809, 2001
9. de Jong SC, van den Berg M, Rauwerda JA, et al: Hyperhomocysteinemia and atherothrombotic disease. Semin Thromb Hemost 24:381-385, 1998
10. Jacobsen DW: Homocysteine and vitamins in cardiovascular disease. Clin Chem 44:1833-1843, 1998
11. D'Angelo A, Selhub J: Homocysteine and thrombotic disease. Blood 90:1-11, 1997
12. Woo KS, Chook P, Lolin YI, et al: Hyperhomocyte(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 96:2542-2544, 1997
13. Maruyama I, Bell CE, Majerus PW: Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncytiotrophoblast of human placenta. J Cell Biol 101:363-371, 1985
14. Esmon CT, Owen WG: Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA 78:2249-2252, 1981
15. Esmon CT: The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 264:4743-4746, 1989
16. Ishii H, Majerus PW: Thrombomodulin is present in human plasma and urine. J Clin Invest 76:2178-2181, 1985
17. Takano S, Kimura S, Ohdama S, et al: Plasma thrombomodulin in health and diseases. Blood 76:2024-2029, 1990
18. Iwashima Y, Sato T, Watanabe K, et al: Elevation of plasma thrombomodulin level in diabetic patients with early diabetic nephropathy. Diabetes 39:983-988, 1990
19. Inukai T, Fujiwara Y, Tayama K, et al: Clinical significance of measurements of urinary and serum thrombomodulin in patients with non-insulin-dependent diabetes mellitus. Diab Res Clin Pract 33:99-104, 1996
20. De Bree A, Verschuren WM, Kromhout D, et al: Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev 54:599-618, 2002
21. Aso Y, Inukai T, Takemura Y: Mechanisms of elevation of serum and urinary thrombomodulin in diabetic patients: Possible application as a market for vascular endothelial injury. Metabolism 47: 362-365, 1998
22. Smulders YM, Rakic M, Slaats EH, et al: Fasting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease. Diabetes Care 22:125-132, 1999
23. Buysschaert M, Dramais AS, Wallemacq PE, et al: Hyperhomocysteinemia in type 2 diabetes: Relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care 23:1816-1822, 2000
24. House JD, Brosnan ME, Brosnan JT: Characterization of homocysteine metabolism in the rat kidney. Biochem J 328:287-292, 1997
25. Miettinen H, Haffner SM, Lehto S, et al: Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 27:2033-2039, 1996
26. Gerstein HC, Mann JF, Yi Q, et al: HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286:421-426, 2001
27. Chico A, Perez A, Cordoba A, et al: Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: A new link between diabetic nephropathy and cardiovascular disease? Diabetologia 41:684-693, 1998
28. Van den Berg M, Boers GH, Franken DG, et al: Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 25:176-181, 1995
29. Becker A, Van Hinsbergh VW, Kostense PJ, et al: Serum homocysteine is weakly associated with von Willebrand factor and soluble vascular cell adhesion molecule 1, but not with C-reactive protein in type 2 diabetic and non-diabetic subjects - The Hoorn Study. Eur J Clin Invest 30:763-770, 2000
30. Hofmann MA, Kohl B, Zumbach MS, et al: Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care 21:841-848, 1998
31. Lentz SR, Sadler JE: Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 88:1906-1914, 1991